#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Diy_coref|
#T_RL=webanno.custom.Diy_coref_re|BT_webanno.custom.Diy_coref


#Text=The isolation and the characteristics of the fetal clone, F55IIIE5 (phenotype CD3.sup.- CD2.sup.+) have been previously described by Nowill et al (1).
1-1	0-3	The	_	_	
1-2	4-13	isolation	_	_	
1-3	14-17	and	_	_	
1-4	18-21	the	_	_	
1-5	22-37	characteristics	_	_	
1-6	38-40	of	_	_	
1-7	41-44	the	_	_	
1-8	45-50	fetal	_	_	
1-9	51-56	clone	_	_	
1-10	56-57	,	_	_	
1-11	58-66	F55IIIE5	_	_	
1-12	67-68	(	_	_	
1-13	68-77	phenotype	_	_	
1-14	78-81	CD3	_	_	
1-15	81-82	.	_	_	
1-16	82-85	sup	_	_	
1-17	85-86	.	_	_	
1-18	86-87	-	_	_	
1-19	88-91	CD2	_	_	
1-20	91-92	.	_	_	
1-21	92-95	sup	_	_	
1-22	95-96	.	_	_	
1-23	96-97	+	_	_	
1-24	97-98	)	_	_	
1-25	99-103	have	_	_	
1-26	104-108	been	_	_	
1-27	109-119	previously	_	_	
1-28	120-129	described	_	_	
1-29	130-132	by	_	_	
1-30	133-139	Nowill	_	_	
1-31	140-142	et	_	_	
1-32	143-145	al	_	_	
1-33	146-147	(	_	_	
1-34	147-148	1	_	_	
1-35	148-149	)	_	_	
1-36	149-150	.	_	_	

#Text=The mass culture was carried out in the presence of recombinant interleukin-2 and the supernatant of lymphocyte-conditioned medium on a feeder substratum of allogenic irradiated mononucleated blood cells and a cell line transformed by the EBV virus (called LAZ 388) on V-bottomed 96-well plates. 3000 cells were placed in each well at day 0.
2-1	151-154	The	_	_	
2-2	155-159	mass	_	_	
2-3	160-167	culture	_	_	
2-4	168-171	was	_	_	
2-5	172-179	carried	_	_	
2-6	180-183	out	_	_	
2-7	184-186	in	_	_	
2-8	187-190	the	_	_	
2-9	191-199	presence	_	_	
2-10	200-202	of	_	_	
2-11	203-214	recombinant	_	_	
2-12	215-226	interleukin	_	_	
2-13	226-227	-	_	_	
2-14	227-228	2	_	_	
2-15	229-232	and	_	_	
2-16	233-236	the	_	_	
2-17	237-248	supernatant	_	_	
2-18	249-251	of	_	_	
2-19	252-274	lymphocyte-conditioned	_	_	
2-20	275-281	medium	_	_	
2-21	282-284	on	_	_	
2-22	285-286	a	_	_	
2-23	287-293	feeder	_	_	
2-24	294-304	substratum	_	_	
2-25	305-307	of	_	_	
2-26	308-317	allogenic	_	_	
2-27	318-328	irradiated	_	_	
2-28	329-342	mononucleated	_	_	
2-29	343-348	blood	_	_	
2-30	349-354	cells	_	_	
2-31	355-358	and	_	_	
2-32	359-360	a	_	_	
2-33	361-365	cell	_	_	
2-34	366-370	line	_	_	
2-35	371-382	transformed	_	_	
2-36	383-385	by	_	_	
2-37	386-389	the	_	_	
2-38	390-393	EBV	_	_	
2-39	394-399	virus	_	_	
2-40	400-401	(	_	_	
2-41	401-407	called	_	_	
2-42	408-411	LAZ	_	_	
2-43	412-415	388	_	_	
2-44	415-416	)	_	_	
2-45	417-419	on	_	_	
2-46	420-430	V-bottomed	_	_	
2-47	431-433	96	_	_	
2-48	433-434	-	_	_	
2-49	434-438	well	_	_	
2-50	439-445	plates	_	_	
2-51	445-446	.	_	_	
2-52	447-451	3000	_	_	
2-53	452-457	cells	_	_	
2-54	458-462	were	_	_	
2-55	463-469	placed	_	_	
2-56	470-472	in	_	_	
2-57	473-477	each	_	_	
2-58	478-482	well	_	_	
2-59	483-485	at	_	_	
2-60	486-489	day	_	_	
2-61	490-491	0	_	_	
2-62	491-492	.	_	_	

#Text=The pooling of 200 plates with 3.times.10.sup.6 cells per ml at day 12 gave a harvest of 6.times.10.sup.9 cells.
3-1	493-496	The	_	_	
3-2	497-504	pooling	_	_	
3-3	505-507	of	_	_	
3-4	508-511	200	_	_	
3-5	512-518	plates	_	_	
3-6	519-523	with	_	_	
3-7	524-525	3	_	_	
3-8	525-526	.	_	_	
3-9	526-531	times	_	_	
3-10	531-534	.10	_	_	
3-11	534-535	.	_	_	
3-12	535-538	sup	_	_	
3-13	538-540	.6	_	_	
3-14	541-546	cells	_	_	
3-15	547-550	per	_	_	
3-16	551-553	ml	_	_	
3-17	554-556	at	_	_	
3-18	557-560	day	_	_	
3-19	561-563	12	_	_	
3-20	564-568	gave	_	_	
3-21	569-570	a	_	_	
3-22	571-578	harvest	_	_	
3-23	579-581	of	_	_	
3-24	582-583	6	_	_	
3-25	583-584	.	_	_	
3-26	584-589	times	_	_	
3-27	589-592	.10	_	_	
3-28	592-593	.	_	_	
3-29	593-596	sup	_	_	
3-30	596-598	.9	_	_	
3-31	599-604	cells	_	_	
3-32	604-605	.	_	_	

#Text=The preparation of the cytoplasmic RNAs, the RNAs bound to the membranes of the endoplasmic reticulum and the mRNAs was performed by introducing some modifications to the methods described by Maniatis (2), Mechler (3) and Aviv (4).
4-1	606-609	The	_	_	
4-2	610-621	preparation	_	_	
4-3	622-624	of	_	_	
4-4	625-628	the	_	_	
4-5	629-640	cytoplasmic	_	_	
4-6	641-645	RNAs	_	_	
4-7	645-646	,	_	_	
4-8	647-650	the	_	_	
4-9	651-655	RNAs	_	_	
4-10	656-661	bound	_	_	
4-11	662-664	to	_	_	
4-12	665-668	the	_	_	
4-13	669-678	membranes	_	_	
4-14	679-681	of	_	_	
4-15	682-685	the	_	_	
4-16	686-697	endoplasmic	_	_	
4-17	698-707	reticulum	_	_	
4-18	708-711	and	_	_	
4-19	712-715	the	_	_	
4-20	716-721	mRNAs	_	_	
4-21	722-725	was	_	_	
4-22	726-735	performed	_	_	
4-23	736-738	by	_	_	
4-24	739-750	introducing	_	_	
4-25	751-755	some	_	_	
4-26	756-769	modifications	_	_	
4-27	770-772	to	_	_	
4-28	773-776	the	_	_	
4-29	777-784	methods	_	_	
4-30	785-794	described	_	_	
4-31	795-797	by	_	_	
4-32	798-806	Maniatis	_	_	
4-33	807-808	(	_	_	
4-34	808-809	2	_	_	
4-35	809-810	)	_	_	
4-36	810-811	,	_	_	
4-37	812-819	Mechler	_	_	
4-38	820-821	(	_	_	
4-39	821-822	3	_	_	
4-40	822-823	)	_	_	
4-41	824-827	and	_	_	
4-42	828-832	Aviv	_	_	
4-43	833-834	(	_	_	
4-44	834-835	4	_	_	
4-45	835-836	)	_	_	
4-46	836-837	.	_	_	

#Text=Thus, 4.times.10.sup.9 F55IIIE5 cells were loaded onto sucrose gradients after hypotonic shock and mechanical grinding according to the method described by Mechler.
5-1	838-842	Thus	_	_	
5-2	842-843	,	_	_	
5-3	844-845	4	_	_	
5-4	845-846	.	_	_	
5-5	846-851	times	_	_	
5-6	851-854	.10	_	_	
5-7	854-855	.	_	_	
5-8	855-858	sup	_	_	
5-9	858-860	.9	_	_	
5-10	861-869	F55IIIE5	_	_	
5-11	870-875	cells	_	_	
5-12	876-880	were	_	_	
5-13	881-887	loaded	_	_	
5-14	888-892	onto	_	_	
5-15	893-900	sucrose	_	_	
5-16	901-910	gradients	_	_	
5-17	911-916	after	_	_	
5-18	917-926	hypotonic	_	_	
5-19	927-932	shock	_	_	
5-20	933-936	and	_	_	
5-21	937-947	mechanical	_	_	
5-22	948-956	grinding	_	_	
5-23	957-966	according	_	_	
5-24	967-969	to	_	_	
5-25	970-973	the	_	_	
5-26	974-980	method	_	_	
5-27	981-990	described	_	_	
5-28	991-993	by	_	_	
5-29	994-1001	Mechler	_	_	
5-30	1001-1002	.	_	_	

#Text=The cytoplasmic RNAs borne by the ribosomes bound to the membranes of the endoplasmic reticulum were purified between sucrose gradients.
6-1	1003-1006	The	_	_	
6-2	1007-1018	cytoplasmic	_	_	
6-3	1019-1023	RNAs	_	_	
6-4	1024-1029	borne	_	_	
6-5	1030-1032	by	_	_	
6-6	1033-1036	the	_	_	
6-7	1037-1046	ribosomes	_	_	
6-8	1047-1052	bound	_	_	
6-9	1053-1055	to	_	_	
6-10	1056-1059	the	_	_	
6-11	1060-1069	membranes	_	_	
6-12	1070-1072	of	_	_	
6-13	1073-1076	the	_	_	
6-14	1077-1088	endoplasmic	_	_	
6-15	1089-1098	reticulum	_	_	
6-16	1099-1103	were	_	_	
6-17	1104-1112	purified	_	_	
6-18	1113-1120	between	_	_	
6-19	1121-1128	sucrose	_	_	
6-20	1129-1138	gradients	_	_	
6-21	1138-1139	.	_	_	

#Text=This makes it possible to work subsequently with mRNAs which have a signal sequence and which consequently code for proteins borne by the membrane or secreted into the internal part of the ergastoplasm (and towards the exterior of the cell).
7-1	1140-1144	This	*[1]	8-1[2_1]	
7-2	1145-1150	makes	*[1]	_	
7-3	1151-1153	it	*[1]	_	
7-4	1154-1162	possible	*[1]	_	
7-5	1163-1165	to	*[1]	_	
7-6	1166-1170	work	*[1]	_	
7-7	1171-1183	subsequently	*[1]	_	
7-8	1184-1188	with	*[1]	_	
7-9	1189-1194	mRNAs	*[1]	_	
7-10	1195-1200	which	*[1]	_	
7-11	1201-1205	have	*[1]	_	
7-12	1206-1207	a	*[1]	_	
7-13	1208-1214	signal	*[1]	_	
7-14	1215-1223	sequence	*[1]	_	
7-15	1224-1227	and	*[1]	_	
7-16	1228-1233	which	*[1]	_	
7-17	1234-1246	consequently	*[1]	_	
7-18	1247-1251	code	*[1]	_	
7-19	1252-1255	for	*[1]	_	
7-20	1256-1264	proteins	*[1]	_	
7-21	1265-1270	borne	*[1]	_	
7-22	1271-1273	by	*[1]	_	
7-23	1274-1277	the	*[1]	_	
7-24	1278-1286	membrane	*[1]	_	
7-25	1287-1289	or	*[1]	_	
7-26	1290-1298	secreted	*[1]	_	
7-27	1299-1303	into	*[1]	_	
7-28	1304-1307	the	*[1]	_	
7-29	1308-1316	internal	*[1]	_	
7-30	1317-1321	part	*[1]	_	
7-31	1322-1324	of	*[1]	_	
7-32	1325-1328	the	*[1]	_	
7-33	1329-1341	ergastoplasm	*[1]	_	
7-34	1342-1343	(	*[1]	_	
7-35	1343-1346	and	*[1]	_	
7-36	1347-1354	towards	*[1]	_	
7-37	1355-1358	the	*[1]	_	
7-38	1359-1367	exterior	*[1]	_	
7-39	1368-1370	of	*[1]	_	
7-40	1371-1374	the	*[1]	_	
7-41	1375-1379	cell	*[1]	_	
7-42	1379-1380	)	*[1]	_	
7-43	1380-1381	.	*[1]	_	

#Text=This method of isolation of RNA of the so-called MB (membrane-bound) type makes it possible to remove right away about 90% of the transcribed genes which code for intracellular proteins incapable of being secreted towards the exterior or transported towards the membrane and, consequently, of no interest in the context of the invention.
8-1	1382-1386	This	*[2]	_	
8-2	1387-1393	method	*[2]	_	
8-3	1394-1396	of	_	_	
8-4	1397-1406	isolation	_	_	
8-5	1407-1409	of	_	_	
8-6	1410-1413	RNA	_	_	
8-7	1414-1416	of	_	_	
8-8	1417-1420	the	_	_	
8-9	1421-1430	so-called	_	_	
8-10	1431-1433	MB	_	_	
8-11	1434-1435	(	_	_	
8-12	1435-1449	membrane-bound	_	_	
8-13	1449-1450	)	_	_	
8-14	1451-1455	type	_	_	
8-15	1456-1461	makes	_	_	
8-16	1462-1464	it	_	_	
8-17	1465-1473	possible	_	_	
8-18	1474-1476	to	_	_	
8-19	1477-1483	remove	_	_	
8-20	1484-1489	right	_	_	
8-21	1490-1494	away	_	_	
8-22	1495-1500	about	_	_	
8-23	1501-1504	90%	_	_	
8-24	1505-1507	of	_	_	
8-25	1508-1511	the	_	_	
8-26	1512-1523	transcribed	_	_	
8-27	1524-1529	genes	_	_	
8-28	1530-1535	which	_	_	
8-29	1536-1540	code	_	_	
8-30	1541-1544	for	_	_	
8-31	1545-1558	intracellular	_	_	
8-32	1559-1567	proteins	_	_	
8-33	1568-1577	incapable	_	_	
8-34	1578-1580	of	_	_	
8-35	1581-1586	being	_	_	
8-36	1587-1595	secreted	_	_	
8-37	1596-1603	towards	_	_	
8-38	1604-1607	the	_	_	
8-39	1608-1616	exterior	_	_	
8-40	1617-1619	or	_	_	
8-41	1620-1631	transported	_	_	
8-42	1632-1639	towards	_	_	
8-43	1640-1643	the	_	_	
8-44	1644-1652	membrane	_	_	
8-45	1653-1656	and	_	_	
8-46	1656-1657	,	_	_	
8-47	1658-1670	consequently	_	_	
8-48	1670-1671	,	_	_	
8-49	1672-1674	of	_	_	
8-50	1675-1677	no	_	_	
8-51	1678-1686	interest	_	_	
8-52	1687-1689	in	_	_	
8-53	1690-1693	the	_	_	
8-54	1694-1701	context	_	_	
8-55	1702-1704	of	_	_	
8-56	1705-1708	the	_	_	
8-57	1709-1718	invention	_	_	
8-58	1718-1719	.	_	_	

#Text=In addition to the isolation of the MB-F55IIIE5 mRNA which serves as substrate for the construction of the library, on the one hand, and the preparation of the probe, on the other, the methods of purification described by Aviv (4), Maniatis (2) and Triebel (5) made possible the isolation of RNAs of the various clones and cell lines which are used and mRNAs of Jurkat, U937, Laz388 and K562 cells (about 10.sup.9 cells of each line) which are used to subtract the probe.
9-1	1720-1722	In	_	_	
9-2	1723-1731	addition	_	_	
9-3	1732-1734	to	_	_	
9-4	1735-1738	the	_	_	
9-5	1739-1748	isolation	_	_	
9-6	1749-1751	of	_	_	
9-7	1752-1755	the	_	_	
9-8	1756-1767	MB-F55IIIE5	_	_	
9-9	1768-1772	mRNA	_	_	
9-10	1773-1778	which	_	_	
9-11	1779-1785	serves	_	_	
9-12	1786-1788	as	_	_	
9-13	1789-1798	substrate	_	_	
9-14	1799-1802	for	_	_	
9-15	1803-1806	the	_	_	
9-16	1807-1819	construction	_	_	
9-17	1820-1822	of	_	_	
9-18	1823-1826	the	_	_	
9-19	1827-1834	library	_	_	
9-20	1834-1835	,	_	_	
9-21	1836-1838	on	_	_	
9-22	1839-1842	the	_	_	
9-23	1843-1846	one	_	_	
9-24	1847-1851	hand	_	_	
9-25	1851-1852	,	_	_	
9-26	1853-1856	and	_	_	
9-27	1857-1860	the	_	_	
9-28	1861-1872	preparation	_	_	
9-29	1873-1875	of	_	_	
9-30	1876-1879	the	_	_	
9-31	1880-1885	probe	_	_	
9-32	1885-1886	,	_	_	
9-33	1887-1889	on	_	_	
9-34	1890-1893	the	_	_	
9-35	1894-1899	other	_	_	
9-36	1899-1900	,	_	_	
9-37	1901-1904	the	_	_	
9-38	1905-1912	methods	_	_	
9-39	1913-1915	of	_	_	
9-40	1916-1928	purification	_	_	
9-41	1929-1938	described	_	_	
9-42	1939-1941	by	_	_	
9-43	1942-1946	Aviv	_	_	
9-44	1947-1948	(	_	_	
9-45	1948-1949	4	_	_	
9-46	1949-1950	)	_	_	
9-47	1950-1951	,	_	_	
9-48	1952-1960	Maniatis	_	_	
9-49	1961-1962	(	_	_	
9-50	1962-1963	2	_	_	
9-51	1963-1964	)	_	_	
9-52	1965-1968	and	_	_	
9-53	1969-1976	Triebel	_	_	
9-54	1977-1978	(	_	_	
9-55	1978-1979	5	_	_	
9-56	1979-1980	)	_	_	
9-57	1981-1985	made	_	_	
9-58	1986-1994	possible	_	_	
9-59	1995-1998	the	_	_	
9-60	1999-2008	isolation	_	_	
9-61	2009-2011	of	_	_	
9-62	2012-2016	RNAs	_	_	
9-63	2017-2019	of	_	_	
9-64	2020-2023	the	_	_	
9-65	2024-2031	various	_	_	
9-66	2032-2038	clones	_	_	
9-67	2039-2042	and	_	_	
9-68	2043-2047	cell	_	_	
9-69	2048-2053	lines	_	_	
9-70	2054-2059	which	_	_	
9-71	2060-2063	are	_	_	
9-72	2064-2068	used	_	_	
9-73	2069-2072	and	_	_	
9-74	2073-2078	mRNAs	_	_	
9-75	2079-2081	of	_	_	
9-76	2082-2088	Jurkat	_	_	
9-77	2088-2089	,	_	_	
9-78	2090-2094	U937	_	_	
9-79	2094-2095	,	_	_	
9-80	2096-2102	Laz388	_	_	
9-81	2103-2106	and	_	_	
9-82	2107-2111	K562	_	_	
9-83	2112-2117	cells	_	_	
9-84	2118-2119	(	_	_	
9-85	2119-2124	about	_	_	
9-86	2125-2127	10	_	_	
9-87	2127-2128	.	_	_	
9-88	2128-2131	sup	_	_	
9-89	2131-2133	.9	_	_	
9-90	2134-2139	cells	_	_	
9-91	2140-2142	of	_	_	
9-92	2143-2147	each	_	_	
9-93	2148-2152	line	_	_	
9-94	2152-2153	)	_	_	
9-95	2154-2159	which	_	_	
9-96	2160-2163	are	_	_	
9-97	2164-2168	used	_	_	
9-98	2169-2171	to	_	_	
9-99	2172-2180	subtract	_	_	
9-100	2181-2184	the	_	_	
9-101	2185-2190	probe	_	_	
9-102	2190-2191	.	_	_	

#Text=These methods comprise:
#Text=A--Preparation of the cytoplasmic RNA.
10-1	2192-2197	These	_	_	
10-2	2198-2205	methods	_	_	
10-3	2206-2214	comprise	_	_	
10-4	2214-2215	:	_	_	
10-5	2216-2217	A	_	_	
10-6	2217-2218	-	_	_	
10-7	2218-2219	-	_	_	
10-8	2219-2230	Preparation	_	_	
10-9	2231-2233	of	_	_	
10-10	2234-2237	the	_	_	
10-11	2238-2249	cytoplasmic	_	_	
10-12	2250-2253	RNA	_	_	
10-13	2253-2254	.	_	_	
